Evidence map›Paper›PMID 36505501›Full record

ArticleFrontiers in immunology2022

Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma.

Qi Wang, Wenying Qiao, Honghai Zhang, Biyu Liu, Jianjun Li, Chaoran Zang, Tingting Mei, Jiasheng Zheng, Yonghong Zhang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qi WangResearch Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Wenying QiaoResearch Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Honghai ZhangInterventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Biyu LiuResearch Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Jianjun LiInterventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Chaoran ZangResearch Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Tingting MeiResearch Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Jiasheng ZhengInterventional Therapy Center for Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
Yonghong ZhangResearch Center for Biomedical Resources, Beijing You'an Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the risk factors for recurrence in patients with early-stage hepatocellular carcinoma (HCC) after minimally invasive treatment with curative intent, then to construct a prediction model based on Lasso-Cox regression and visualize the model built. Methods: Clinical data were collected from 547 patients that received minimally invasive treatment in our hospital from January 1, 2012, to December 31, 2016. Lasso regression was used to screen risk factors for recurrence. Then we established Cox proportional hazard regression model and random survival forest model including several parameters screened by Lasso regression. An optimal model was selected by comparing the values of C-index, then the model was visualized and the nomogram was finally plotted. Results: The variables screened by Lasso regression including age, gender, cirrhosis, tumor number, tumor size, platelet-albumin-bilirubin index (PALBI), and viral load were incorporated in the Cox model and random survival forest model (P<0.05). The C-index of these two models in the training sets was 0.729 and 0.708, and was 0.726 and 0.700 in the validation sets, respectively. So we finally chose Lasso-Cox regression model, and the calibration curve in the validation set performed well, indicating that the model built has a better predictive ability. And then a nomogram was plotted based on the model chosen to visualize the results. Conclusions: The present study established a nomogram for predicting recurrence in patients with early-stage HCC based on the Lasso-Cox regression model. This nomogram was of some guiding significance for screening populations at high risk of recurrence after treatment, by which doctors can formulate individualized follow-up strategies or treatment protocols according to the predicted risk of relapse for patients to improve the long-term prognosis.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansLiver CirrhosisNeoplasm Recurrence, LocalNomogramshepatocellular carcinomaLasso-Cox regressionnomogrampredictionrecurrence

Identifiers

PMID36505501
PMCPMC9726717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.